AUS
NZ
UK
CA
USA
IND
Healthcare
ASX 200 Biotech Watch: Telix’s ProstACT Trial and Valuation
December 11, 2025 03:29 PM AEDT| By SamTelix Pharmaceuticals advances its ProstACT Global Phase 3 trial while trading at a discount to several valuation lenses, leaving the market to weigh maturing radiopharma potential against familiar clinical and execution risks.
Liontown’s Canmax Deal: ASX 200 Lithium Story
December 11, 2025 03:14 PM AEDT| By SamLiontown’s new Canmax offtake deepens global customer reach and demand visibility, but the real test remains underground delivery, cost control and navigating a volatile lithium cycle as Kathleen Valley matures.
Racura Oncology Renamed as HARNESS-1 Trial Moves Forward
December 11, 2025 11:30 AM AEDT| By SamThis article explores Racura Oncology’s (ASX:RAC) name change, the progress of its HARNESS-1 trial, and the expanding clinical direction shaping the company’s role in cancer treatment innovation.
CSL Update: Buyback Signal, Seqirus Scrutiny and Key Watchpoints
December 10, 2025 08:32 PM AEDT| By SamCSL is balancing buyback activity with heightened attention on Seqirus and public procurement scrutiny. Investors are watching manufacturing consistency, margin stabilisation, and whether external headlines ease as execution improves.
Remplir’s Hong Kong Launch Signals Stronger Asian Reach for Orthocell
December 10, 2025 04:57 PM AEDT| By SamOrthocell (ASX:OCC) advances its Asian and global medical device presence with Remplir’s first Hong Kong sales, supporting wider adoption across major regions and strengthening its regenerative medicine strategy.
ASX 200 Watch: Artrya’s US Hospital Win Signals Momentum
December 10, 2025 03:53 PM AEDT| By SamArtrya’s US hospital agreement puts Salix into real-world care pathways, strengthening credibility and commercial momentum. The next chapter hinges on routine adoption, smooth scaling, and repeatable deployments.
Hong Kong Debut Strengthens Remplir’s Global Growth Path
December 10, 2025 03:51 PM AEDT| By SamOrthocell (ASX:OCC) expands Remplir’s reach with first sales in Hong Kong, strengthening its regional and global commercial rollout.
PharmX in Focus: Is This Pharmacy Network Moat Built to Last?
December 10, 2025 03:34 PM AEDT| By SamPharmX supports pharmacy procurement workflows across Australia and New Zealand. Network effects can support strong economics, while competition, adoption of new services, and cash discipline remain the core factors to track.
4DMedical (ASX:4DX): Growth Story Gains Airflow in the US Market
December 10, 2025 02:51 PM AEDT| By Sam4DMedical’s CT:VQ rollout is gathering pace in the US via Philips distribution and new hospital partners. The focus now shifts to scan volumes, execution, and cash burn control.
Health Check: Cogstate (ASX:CGS) Downgrade and What’s Next
December 10, 2025 02:34 PM AEDT| By SamCogstate’s share price dropped after a revenue and earnings downgrade tied to contract timing and margin mix. The outlook hinges on conversion, delivery timing, and second-half execution.
4DMedical (ASX:4DX) and the ASX 200: US Momentum Builds
December 10, 2025 02:29 PM AEDT| By Sam4DMedical is building US momentum for CT:VQ through institutional adoption and distribution pathways. The focus now is repeatable utilisation growth, where scale benefits are possible but rollout execution remains critical.
Racura Oncology’s New Chapter as HARNESS-1 Moves Ahead
December 10, 2025 12:31 PM AEDT| By SamRacura Oncology (ASX:RAC) advances its HARNESS-1 program with a refreshed identity and strengthened clinical roadmap, marking a new growth phase within the evolving Australian biotechnology landscape.
Clarity Pharmaceuticals (ASX:CU6) Poised for Breakthrough Performance
December 09, 2025 07:45 PM AEDT| By SamClarity Pharmaceuticals (ASX:CU6) nears breakeven with debt-free operations, strong growth prospects, and a focus on oncology radiopharmaceuticals in the ASX stock market.
Ramsay Health Care (ASX:RHC): Low Valuation Signals Need for Caution
December 09, 2025 07:28 PM AEDT| By SamExplore why Ramsay Health Care’s (ASX:RHC) low valuation reflects revenue slowdown and industry caution, highlighting its position within the broader ASX stock market.
Race Oncology Advances HARNESS-One Lung Cancer Trial Funding
December 09, 2025 05:15 PM AEDT| By SamA detailed look at how Race Oncology (ASX:RAC) is advancing its HARNESS-One lung cancer trial through fresh funding, regulatory progress, and a clear clinical roadmap.
Fresh Funding Clears Path for Race Oncology’s HARNESS-1 Trial
December 09, 2025 04:58 PM AEDT| By SamRace Oncology (ASX:RAC) has strengthened the pathway for its HARNESS-1 study after securing additional capital, ensuring the study of RC220 in lung cancer moves into its next phase.
ASX 200: Race Oncology Funds HARNESS Trial Start
December 09, 2025 03:41 PM AEDT| By SamRace Oncology has secured additional funding to initiate its HARNESS study of RC two two zero with osimertinib in lung cancer. With ethics authorisation secured, attention turns to site activation and enrolment milestones.
Race Oncology Secures Fresh Backing to Advance HARNESS-1 Trial
December 09, 2025 11:54 AM AEDT| By SamThis article explores how Race Oncology (ASX:RAC) gained additional backing to move ahead with its HARNESS-1 trial, outlining its significance for clinical development and the broader healthcare landscape on the ASX.
Global Licensing Lift Sends Immutep Shares Into Spotlight
December 09, 2025 11:41 AM AEDT| By SamThis article explores Immutep’s new global licensing deal, how it strengthens international access for its lead therapy, and why the development has drawn attention across the broader ASX healthcare landscape.
Artrya Secures Key US Commercial Deal for AI Cardiovascular Platform
December 08, 2025 05:44 PM AEDT| By SamArtrya (ASX:AYA) secures second US commercial order for Salix AI platform, enhancing coronary artery disease management and patient care across Georgia healthcare networks.
Advertise your brand on Kalkine Media